Health Partners

## HEALTH PARTNERS PLANS 2024 PRIOR AUTHORIZATION REQUEST FORM

Bexarotene 1% Gel (Non-PDL)

A part of Jefferson Health Plans

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:		
HPP HPP Member Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Patient Primary Phone:	NPI:	PA PROMISe ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Line of Business:	Specialty Pharma	ncy (if applicable):	
Drug Name:	Strength:		
Quantity:	Refills:		
Directions:			
Diagnosis Code:	Diagnosis:		
HPP's maximum approval time is 12 months but may be less depending on the drug.			
Please attach any pertinent medical history including labs and information for this member that may support approval.			

Please answer the following questions and sign.			
Q1. Is this a renewal request? If yes, go to 2. If no, go to 5.			
□ Yes	🗆 No		
Q2. Has the patient been previously approved for bexarotene gel for the treatment of cutaneous lesions in patients with CTCL?			
□ Yes	□ No		
Q3. Is the patient female?			
□ Yes	🗆 No		
Q4. Is there a confirmed negative pregnancy test and contraception plan in place throughout treatment course?			
□ Yes	🗆 No		
Q5. Is the patient equal to or greater than 18 years of age?			
□ Yes	🗆 No		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



## HEALTH PARTNERS PLANS 2024 PRIOR AUTHORIZATION REQUEST FORM

A part of Jefferson Health Plans

Bexarotene 1% Gel (Non-PDL)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:	
Q6. Is the medication being prescribed by or in or dermatologist?	consultation with an oncologist or	
□ Yes	□ No	
Q7. Is this prescribed for the treatment of an FDA approved indication?		
□ Yes	□ No	
Q8. Does the patient have an intolerance, contraindication or therapeutic failure to one prior treatment: such as surgical excision, radiation, phototherapy, topical corticosteroids, topical imiquimod, systemic or topical chemotherapy (mechlorethamine [nitrogen mustard], carmustine)?		
□ Yes	□ No	
Q9. Is the patient a female?		
□ Yes	□ No	
Q10. Is there a confirmed negative pregnancy test prior to starting therapy and contraception plan in place throughout treatment course?		
□ Yes	□ No	
Q11. Additional Information:		

Prescriber Signature

Date

Updated for 2024

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document